Finorex is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription. Finerenone blocks MR mediated sodium reabsorption and MR overactivation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, and blood vessels) tissues. MR overactivation is thought to contribute to fibrosis and inflammation. Finerenone has a high potency and selectivity for the MR and has no relevant affinity for androgen, progesterone, estrogen and glucocorticoid receptors. In patients treated with Finerenone, the mean systolic blood pressure decreased by 3 mmHg and the mean diastolic blood pressure decreased by 1-2 mmHg at month 1, remaining stable thereafter. At a dose 4 times the maximum approved recommended dose, Finerenone does not prolong the QT interval to any clinically relevant extent. Finerenone is completely absorbed after oral administration but undergoes metabolism resulting in absolute bioavailability of 44%. Finerenone C_max was achieved between 0.5 and 1.25 hours after dosing.

Finerenone exposure increased proportionally over a dose range of 1.25 to 80 mg (0.06 to 4 times the maximum approved recommended dosage). Steady state of finerenone was achieved after 2 days of dosing. The estimated steady-state geometric mean Cmax, md was 160 μg/L and steady-state geometric mean AUCt,md was 686 μg.h/L following administration of finerenone 20 mg to patients.

Absorption: Finerenone is completely absorbed after oral administration but undergoes metabolism resulting in absolute bioavailability of 44%. Finerenone Cmax was achieved between 0.5 and 1.25 hours after dosing. Effect of Food There was no clinically significant effect on finerenone AUC following administration with high fat, high calorie food.

Distribution: The volume of distribution at steady-state (Vss) of finerenone is 52.6 L. Plasma protein binding of finerenone is 92%, primarily to serum albumin, in vitro.

Elimination: The terminal half-life of finerenone is about 2 to 3 hours, and the systemic blood clearance is about 25 L/h.

Metabolism: Finerenone is primarily metabolized by CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%) to inactive metabolites. Excretion About 80% of the administered dose is excreted in urine

The recommended starting dosage: 10 mg or 20 mg orally once daily based on estimated glomerular filtration rate (eGFR) and serum potassium thresholds. Increase dosage after 4 weeks to the target dose of 20 mg once daily, based on eGFR and serum potassium thresholds. Tablets may be taken with or without food.

Recommended Dosage-

• eGFR ≥60 mL/min/1.73 m²: starting dose 20 mg once daily
• eGFR ≥25 to <60 mL/min/1.73 m²: starting dose 10 mg once daily
• eGFR <25 mL/min/1.73 m²: not recommended

For patients who are unable to swallow whole tablets, Finerenone may be crushed and mixed with water or soft foods.

Monitoring and Dose Adjustment: The target daily dose of Finerenone is 20 mg. Measure serum potassium 4 weeks after initiating treatment and adjust dose (see Table 2); if serum potassium levels are > 4.8 to 5.0 mEq/L, initiation of Finerenone treatment may be considered with additional serum potassium monitoring within the first 4 weeks based on clinical judgment and serum potassium levels. Monitor serum potassium 4 weeks after a dose adjustment and throughout treatment and adjust the dose as needed.

Missed doses: Direct a patient to take a missed dose as soon as possible after it is noticed, but only on the same day. If this is not possible, the patient should skip the dose and continue with the next dose as prescribed.

Strong CYP3A4 Inhibitors: Finorex is a CYP3A4 substrate. Concomitant use with a strong CYP3A4 inhibitor increases Finorex exposure, which may increase the risk of Finorex adverse reactions. Concomitant use of Finorex with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice.

Moderate and Weak CYP3A4 Inhibitors: Finorex is a CYP3A4 substrate. Concomitant use with a moderate or weak CYP3A4 inhibitor increases Finorex exposure, which may increase the risk of Finorex adverse reactions. Monitor serum potassium during drug initiation or dosage adjustment of either Finorex or the moderate or weak CYP3A4 inhibitor, and adjust Finorex dosage as appropriate.

Strong and Moderate CYP3A4 Inducers: Finorex is a CYP3A4 substrate. Concomitant use of Finorex with a strong or moderate CYP3A4 inducer decreases Finorex exposure, which may reduce the efficacy of Finorex. Avoid concomitant use of Finorex with strong or moderate CYP3A4 inducers.

Contraindicated in concomitant use with strong CYP3A4 inhibitors & patients with adrenal insufficiency.

Adverse reactions occurring in ≥ 1% of patients on Finorex and more frequently than placebo are hyperkalemia, hypotension, and hyponatremia.

There are no available data on Kerendia use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal studies have shown developmental toxicity at exposures about 4 times those expected in humans. The clinical significance of these findings is unclear. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

There are no data on the presence of finerenone or its metabolite in human milk, the effects on the breastfed infant or the effects of the drug on milk production. In a pre-and postnatal developmental toxicity study in rats, increased pup mortality and lower pup weight were observed at about 4 times the AUC unbound expected in humans. These findings suggest that finerenone is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential risk to breastfed infants from exposure to Finerenone, avoid breastfeeding during treatment and for 1 day after treatment.

Finorex can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with Finorex and dose accordingly. Do not initiate Finorex if serum potassium is > 5.0 mEq/L. Measure serum potassium periodically during treatment with Finorex and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium.

Pediatric Use: The safety and efficacy of Finorex have not been established in patients below 18 years of age.

Geriatric Use: Of the 2827 patients who received Finorex in the FIDELIO-DKD study, 58% of patients were 65 years and older, and 15% were 75 years and older. No overall differences in safety or efficacy were observed between these patients and younger patients. No dose adjustment is required.

Hepatic Impairment: Avoid use of Finorex in patients with severe hepatic impairment (Child Pugh C). No dosage adjustment is recommended in patients with mild or moderate hepatic impairment (Child Pugh A or B). Consider additional serum potassium monitoring in patients with moderate hepatic impairment (Child Pugh B)

In the event of suspected overdose, immediately interrupt Finorex treatment. The most likely manifestation of overdose is hyperkalemia. If hyperkalemia develops, standard treatment should be initiated. Finorex is unlikely to be efficiently removed by hemodialysis given its fraction bound to plasma proteins of about 90%.

Mineralocorticoid Receptor Antagonists

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.